N-((3S)-1-bromo-2-oxo-5-methyl-3-hexyl)-t-butoxycarboxamide | 52716-49-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-((3S)-1-bromo-2-oxo-5-methyl-3-hexyl)-t-butoxycarboxamide
• 英文别名: (3S)-1-bromo-3-(t-butoxycarbonylamino)-5-methyl-2-hexanone；(3S)-1-bromo-3-[(tert-butyloxycarbonyl)amino]-5-methyl-2-oxohexane；tert-butyl N-[(3S)-1-bromo-5-methyl-2-oxohexan-3-yl]carbamate
• CAS: 52716-49-1
• 化学式: C₁₂H₂₂BrNO₃
• 分子量: 308.216
• InChiKey: SUVXZTLARLVLOJ-VIFPVBQESA-N

物化性质

• 熔点：
  76-78 °C
• 沸点：
  369.5±22.0 °C(Predicted)
• 密度：
  1.232±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-((3S)-1-bromo-2-oxo-5-methyl-3-hexyl)-t-butoxycarboxamide 在 platinum(IV) oxide 、 四(三苯基膦)钯 吡啶 、 盐酸 、 4-二甲氨基吡啶 、 sodium tetrahydroborate 、 氢气 、 tin(II) acetate 、 三氧化硫吡啶 、 sodium hydride 、 1-羟基苯并三唑 、 溶剂黄146 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 二乙胺 、 三乙胺 、 N,N-二异丙基乙胺 、 三氟乙酸 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 乙二醇甲醚 、 水 、 二甲基亚砜 、 N,N-二甲基甲酰胺 为溶剂， 反应 205.83h， 生成 N-{(S)-1-[(2R,3S,7S,10S,13S)-3-Benzyloxycarbonylamino-7-((S)-1-carbamoyl-3-methyl-butylcarbamoyl)-10-isobutyl-2-methyl-4,9,12,15-tetraoxo-1-oxa-5,11-diaza-cyclopentadec-13-ylcarbamoyl]-2-methyl-propyl}-succinamic acid
  参考文献：
  名称：

  Synthesis and Evaluation of Macrocyclic Transition State Analogue Inhibitors for α-Chymotrypsin

  摘要：

  Lactams 1 and 2 are readily formed from acyclic precursors in the presence of trypsin and chymotrypsin, respectively, identifying the macrocyclic ring system as a potential motif for constrained transition state analogue inhibitors of the serine peptidases. Ketone 3 was synthesized and shown to be a modest inhibitor of chymotrypsin (K-i = 220 muM), albeit 4-fold more potent than the acyclic hydroxy acid 25 (K-i = 1.5 mM as a mixture of epimers). A precursor (31) to the amino boronic acid 4 was also prepared; although this derivative was a potent inhibitor of chymotrypsin (K-i = 130 nM) by virtue of the boronic acid moiety, it showed no advantage over the des-amino analogue 32 (K-i = 120 nM), which is not capable of cyclizing.

  DOI：

  10.1021/jo034837z
• 作为产物：
  描述：

  ethoxycarbonyl (2S)-4-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoate 在 氢溴酸 作用下， 以 四氢呋喃 、 乙醚 、 水 为溶剂， 反应 0.58h， 生成 N-((3S)-1-bromo-2-oxo-5-methyl-3-hexyl)-t-butoxycarboxamide
  参考文献：
  名称：

  One-pot synthesis of orthogonally protected dipeptide selenazoles employing Nα-amino selenocarboxamides and α-bromomethyl ketones

  摘要：

  A simple and efficient protocol for the synthesis of selenazole containing dipeptidomimetics using N-alpha-amino selenocarboxamides and alpha-bromomethyl ketones is described. All the compounds made were isolated in good yields and fully characterized. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2014.10.085

文献信息

• Inhibition of aminopeptidases by peptides containing ketomethylene and hydroxyethylene amide bond replacements
  作者：Scott L. Harbeson、Daniel H. Rich

  DOI：10.1021/jm00126a039

  日期：1989.6

  been prepared by the synthesis of peptide substrate analogues in which the scissile amide bond has been replaced with the hydrolytically stable ketomethylene (-COCH2-) and hydroxyethylene [-CH(OH)CH2-] functionalities. Two synthetic strategies were used to prepare the inhibitors, and the advantages and disadvantages of each are discussed. The synthesis of peptides that contain the hydroxyethylene isostere

  氨基肽酶的抑制剂是通过合成肽底物类似物制备的，其中易裂的酰胺键已被水解稳定的酮亚甲基（-CO -）和羟基乙烯[-CH（OH）CH2-]官能团取代。使用了两种合成策略来制备抑制剂，并讨论了每种策略的优缺点。竞争性的内酯和内酰胺的形成使含有羟乙烯等排异构体的肽的合成变得复杂，并且尝试制备游离的N-末端二肽羟乙烯等排异构体的尝试是不成功的。检查的所有酮亚甲基等位基因都是亮氨酸氨基肽酶和氨基肽酶M的弱抑制剂。但是，酮亚甲基抑制剂LysK（RS）Phe（58）（Ki = 4 nM）是与天然产物相当的有效抑制剂，arphamenine A（ArgKPhe; Ki = 2.5 nM）。在不存在镁离子的情况下，观察到正常的Michaelis-Menten动力学抑制膜亮氨酸氨基肽酶的动力学，但在存在Mg2 +的情况下获得了非线性动力学。
• MODULATORS OF AMYLOID BETA
  申请人：Baumann Karlheinz

  公开号：US20080280948A1

  公开（公告）日：2008-11-13

  The invention relates to compounds of formula wherein hetaryl I, hetaryl II, and R 1 are as described herein. Compounds of formula I are modulators for amyloid beta and thus, they may be useful for the treatment or prevention of a disease associated with the deposition of β-amyloid in the brain, in particular Alzheimer's disease.

  该发明涉及公式的化合物，其中hetaryl I、hetaryl II和R1如本文所述。公式I的化合物是淀粉样蛋白β的调节剂，因此它们可能对与大脑中β-淀粉样蛋白沉积相关的疾病的治疗或预防有用，特别是阿尔茨海默病。
• Novel Solution- and Solid-Phase Syntheses of Heterocyclic Systems
  作者：Gaelle Cabon、Berangere Gaucher、Aline Gegout、Sophie Heulle、Thierry Masquelin

  DOI：10.2533/000942903777679280

  日期：——

  Heterocyclic compounds are an attractive source of screening library structures because they possess varied structural diversity and can exhibit potent biological activity. In this context, we present some of our new and versatile approaches to rapid and efficient syntheses of pharmacologically relevant core structures. These include: combination of both solution- and solid-phase processes in the synthesis of pyrazolo[1,5-a]-[1,3,5]-triazin-4-ones and pyrazolo[1,5-a]-[1,3,5]-triazines; parallel, multi-generation synthesis of highly functionalized heterocyclic compounds in solution; a multi-step synthesis of 2,5-diketopiperazine on solid support taking advantage of a bicyclic ?-lactam scaffold, and a combined solid- and solution-phase synthesis of a new class of 2,4-diaminothiazoles.

  杂环化合物是筛选库结构的有吸引力的来源，因为它们具有多样的结构多样性并且可能表现出强大的生物活性。在这个背景下，我们提出了一些新的和多功能的方法，用于快速、高效地合成药理学相关的核心结构。这些方法包括：在合成吡唑并[1,5-a]-[1,3,5]-三唑酮和吡唑并[1,5-a]-[1,3,5]-三嗪时结合溶液相和固相过程；在溶液中并行、多代合成高度官能化的杂环化合物；利用双环β-内酰胺支架在固相上多步合成2,5-二酮哌嗪；以及结合固相和溶液相合成一类新的2,4-二氨基噻唑化合物。
• Nitrogen-containing 5-membered cyclic compounds and drugs containing these compounds as the active ingredient
  申请人：——

  公开号：US20030153508A1

  公开（公告）日：2003-08-14

  An N-containing five-membered ring compound of formula (I) 1 wherein all symbols are the same as described in the specification, and a non-toxic salt thereof. The compound of formula (I) has an inhibitory activity against cysteine protease and therefore it is useful as an agent for the prophylaxis and/or treatment of inflammatory diseases, diseases induced by apoptosis, diseases induced by disorders of immune responses, autoimmune diseases, diseases induced by decomposition of proteins which compose organism, shock, circulatory system disorders, blood coagulation systems disorders, malignant tumors, acquired immune deficiency syndrome (AIDS) and AIDS-related complex (ARC), parasitic diseases, nerve degeneration diseases, pulmonary disorders, bone resorption diseases, endocrinesthenia, etc.

  式（I）的N-含有五元环化合物，其中所有符号如规范中所述，并且其非毒性盐。式（I）的化合物对半胱氨酸蛋白酶具有抑制活性，因此它可用作预防和/或治疗炎症性疾病、凋亡诱导的疾病、免疫反应紊乱引起的疾病、自身免疫疾病、由组成生物体的蛋白质分解引起的疾病、休克、循环系统紊乱、血液凝血系统紊乱、恶性肿瘤、获得性免疫缺陷综合症（AIDS）和AIDS相关综合症（ARC）、寄生虫病、神经退行性疾病、肺部疾病、骨吸收疾病、内分泌衰弱等方面具有用途。
• Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient
  申请人：——

  公开号：US20030162964A1

  公开（公告）日：2003-08-28

  A benzene-fused heteroring derivative of formula (I) 1 , wherein all symbols are the same as described in the specification, and a non-toxic salt thereof. The compound of formula (I) has an inhibitory activity against cysteine protease and therefore it is useful as an agent for the prophylaxis and/or treatment of immune diseases (autoimmune diseases, infectious diseases, etc.), inflammatory diseases (inflammatory bowel diseases, multiple cerebrosclerosis, arthritis, etc.), nerve degeneration diseases (Alzheimer's disease, muscular dystrophy, etc.), bone resorption diseases (osteoporosis, etc.), respiratory system diseases, diabetes, shock, etc.

  式(I)1的苯融合杂环衍生物，其中所有符号与说明书中描述的相同，并其非毒性盐。式(I)的化合物对半胱氨酸蛋白酶具有抑制活性，因此可用作预防和/或治疗免疫疾病（自身免疫疾病、传染病等）、炎症性疾病（炎症性肠病、多发性硬化、关节炎等）、神经退行性疾病（阿尔茨海默病、肌营养不良等）、骨吸收疾病（骨质疏松症等）、呼吸系统疾病、糖尿病、休克等。